分组1 - The company, Aquestive Therapeutics, is advancing medicines to improve patients' lives through innovative science and delivery technologies [2] - It operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [2] - The company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents [2] 分组2 - The company is advancing Anaphylm™ (dibutepinephrine) sublingual film for severe allergic reactions, including anaphylaxis [2] - AQST-108 (epinephrine prodrug) topical gel is being developed for various dermatological conditions, including alopecia areata [2] - The AdrenaVerse™ platform contains a library of over 20 epinephrine prodrugs for potential allergy and dermatological indications [2] 分组3 - Dr. Greenhawt will receive an equity award of 75,000 Restricted Stock Units and 50,000 non-qualified common stock options under the 2022 Equity Inducement Plan [1] - The equity awards will vest 25% after each of the first and second anniversaries of the grant date, and 50% on the third anniversary [1] - The awards were approved by the independent Compensation Committee as a material inducement for Dr. Greenhawt's acceptance of employment [1]

Core Insights - Aquestive Therapeutics, Inc. is participating in four upcoming investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders [1] Company Overview - Aquestive is a pharmaceutical company focused on improving patients' lives through innovative science and delivery technologies [2] - The company is a leader in oral film medication delivery and operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [2] - Headquartered in New Jersey, the company has U.S.-based manufacturing facilities in Indiana and is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents [2] - The company utilizes proprietary technologies like PharmFilm® and has a library of over 20 epinephrine prodrugs within its AdrenaVerse™ platform, targeting various allergy and dermatological indications [2] Product Development - Aquestive is advancing Anaphylm™ (dibutepinephrine) sublingual film for treating severe allergic reactions, including anaphylaxis [2] - The company is also developing AQST-108 (epinephrine prodrug) topical gel for potential dermatological conditions, including alopecia areata [2] Upcoming Events - Management will be available for one-on-one meetings at the TD Cowen 46th Annual Health Care Conference on March 3rd [6] - A fireside chat is scheduled for March 9th at the Leerink Partners Global Healthcare Conference 2026, with additional one-on-one meetings available [6] - A presentation will take place on March 10th at the Citizens Life Sciences Conference, along with one-on-one meetings [6] - Management will also be available for one-on-one meetings on March 11th at the Barclays 28th Annual Global Healthcare Conference [6]